JanA.BurgerMD

PubMed

• A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
  Paul Joseph Hampel, Kerry A Rogers, Wei Ding, Saad S Kenderian, Sameer A Parikh, Mahesh Swaminathan, Erin M Parry, Jan A Burger, Matthew S Davids, Alessandra Ferrajoli...> ;Blood Advances. 2024 Mar 27
• Chronic Lymphocytic Leukemia: Disease Biology.
  Stefan Koehrer, Burger, J.> ;Acta Haematologica. 2024 Jan 1
• Chronic Lymphocytic Leukemia: Novel Perspectives - How to Teach an Old Dog New Tricks.
  Tadmor, T., Burger, J.> ;Acta Haematologica. 2024 Jan 1
• 1 citations
  Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
  Firas M Safa, Terri Rasmussen, Lorena Fontan, Min Xia, Ari Melnick, Patricia Lobelle-Rich, Jan A Burger, Yara Mouawad, Hana Safah, Erik K Flemington, Nakhle S Saba, Wi...> ;Haematologica. 2023 Sep 28
• Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
  Jayastu Senapati, Warren C Fiskus, Naval Daver, Nathaniel R Wilson, Farhad Ravandi, Guillermo Garcia-Manero, Tapan Kadia, Courtney D DiNardo, Elias Jabbour, Jan Burger...> ;Clinical Cancer Research. 2023 Nov 1
• Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.
  Laura M Roccograndi, Alexandra R Lovell, Alessandra Ferrajoli, Philip A Thompson, Jan A Burger, William G Wierda, Nitin Jain, Caitlin R Rausch> ;Leukemia & Lymphoma. 2023 Sep 1
• 2 citations
  Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
  Max J Gordon, Jade E Jones, Binsah George, Christine Peterson, Jan A Burger, Nitin Jain, Michael Keating, William G Wierda, Jean-Bernard Durand, Alessandra Ferrajoli> ;Cancer. 2023 Jul 15
• Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from A...
  Fieke W Hoff, Ti'ara L Griffen, Brandon D Brown, Terzah M Horton, Jan Burger, William Wierda, Stefan E Hubner, Yihua Qiu, Steven M Kornblau> ;International Journal of Molecular Sciences. 2023 Mar 13
• Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia.
  Ti'ara L Griffen, Fieke W Hoff, Yihua Qiu, Jan Burger, William Wierda, Steven M Kornblau> ;International Journal of Molecular Sciences. 2023 Mar 13
• 1 citations
  Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.
  Jennifer A Woyach, Paul M Barr, Thomas J Kipps, Jacqueline C Barrientos, Inhye E Ahn, Paolo Ghia, Vincent Girardi, Emily Hsu, Mandy Jermain, Jan A Burger> ;Cancers. 2023 Jan 13
• Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
  Paul M Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A Burger, Peter Hillmen, Claire Dearden, Sebastian Grosicki, Helen McCarthy, Jian Yong...> ;Future Oncology. 2023 Jan 9
• Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report.
  Anna-Eve Turcotte, William F Glass, Jamie S Lin, Jan A Burger> ;Leukemia Research Reports. 2023 Jan 1
• 22 citations
  A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.
  Nitin Jain, Jayastu Senapati, Beenu Thakral, Alessandra Ferrajoli, Philip Thompson, Jan Burger, Sreyashi Basu, Tapan Kadia, Naval Daver, Gautam Borthakur, Marina Konop...> ;Blood Advances. 2023 May 23
• 39 citations
  Molecular map of chronic lymphocytic leukemia and its impact on outcome.
  Binyamin A Knisbacher, Ziao Lin, Cynthia K Hahn, Ferran Nadeu, Martí Duran-Ferrer, Kristen E Stevenson, Eugen Tausch, Julio Delgado, Alex Barbera-Mourelle, Amaro Taylo...> ;Nature Genetics. 2022 Nov 1
• 4 citations
  TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
  Hua-Jay J Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, Guilin Tang, Jan Burger, Philip Thompson, Alessandra Ferrajoli, Zeev Estrov, Koji Sasaki, Deepa Sampath, Xuem...> ;American Journal of Hematology. 2022 Aug 1
• 86 citations
  Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
  Paul M Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A Burger, Peter Hillmen, Steve E Coutre, Claire Dearden, Sebastian Grosicki, Helen McC...> ;Blood Advances. 2022 Jun 14
• 7 citations
  Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic fe...
  Jan A Burger, Tadeusz Robak, Fatih Demirkan, Osnat Bairey, Carol Moreno, David Simpson, Talha Munir, Don A Stevens, Sandra Dai, Leo W K Cheung, Kevin Kwei, Indu Lal, E...> ;Leukemia & Lymphoma. 2022 Jun 1
• 4 citations
  STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.
  Uri Rozovski, Ivo Veletic, David M Harris, Ping Li, Zhiming Liu, Preetesh Jain, Taghi Manshouri, Alessandra Ferrajoli, Jan A Burger, Prithviraj Bose, Phillip A Thompso...> ;Journal of Immunology. 2022 Jun 15
• 7 citations
  Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures.
  Alicia M Vaca, Nikolaos Ioannou, Mariela Sivina, Elisavet Vlachonikola, Karen Clise-Dwyer, Ekaterina Kim, Dan Li, Qing Ma, Alessandra Ferrajoli, Zeev Estrov, William G...> ;Leukemia. 2022 May 1
• 11 citations
  A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
  Nicholas J Short, Gautam Borthakur, Naveen Pemmaraju, Courtney D Dinardo, Tapan M Kadia, Elias Jabbour, Marina Konopleva, Walid Macaron, Jing Ning, Junsheng Ma, Sherry...> ;Leukemia & Lymphoma. 2022 Sep 1
• 1 citations
  Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
  Akash Mukherjee, Denái R Milton, Elias J Jabbour, Alison M Gulbis, Tapan Kadia, Nitin Jain, Celina Ledesma, Jan Burger, Alessandra Ferrajoli, William Wierda, L Jeffrey...> ;Leukemia & Lymphoma. 2022 Apr 1
• 4 citations
  Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets.
  Ti'ara L Griffen, Fieke W Hoff, Yihua Qiu, James W Lillard Jr, Alessandra Ferrajoli, Philip Thompson, Endurance Toro, Kevin Ruiz, Jan Burger, William Wierda, Steven M ...> ;Blood Cancer Journal. 2022 Mar 17
• 20 citations
  Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
  Gavin Cull, Jan A Burger, Stephen Opat, David Gottlieb, Emma Verner, Judith Trotman, Paula Marlton, Javier Munoz, Patrick Johnston, David Simpson, Jennifer C Stern, Ra...> ;British Journal of Haematology. 2022 Mar 1
• 8 citations
  B-cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia
  Andrea Nicola Mazzarello, Eva Gentner-Göbel, Marcus Dühren-von Minden, Tatyana N. Tarasenko, Antonella Nicolò, Gerardo Ferrer, Stefano Vergani, Yun Liu, Kanti R. Rai, ...> ;The Journal of Clinical Investigation. 2021 Nov 23
• 3 citations
  RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences
  Anneke D. van Dijk, Ti’ara L. Griffen, Yihua Qiu, Fieke W Hoff, Endurance Toro, Kevin Ruiz, Peter P. Ruvolo, James W. Lillard, Eveline S. J. M. de Bont, Jan A. Burger,...> ;Leukemia. 2021 Oct 8
• Join now to see all

Journal Articles

• Sustained Efficacy and Detailed Clinical Follow-up of First-Line Ibrutinib Treatment in Older Patients with Chronic Lymphocytic Leukemia: Extended Phase 3 Results from...  
  Steven Coutre, Thomas J Kipps, Jan A Burger, Nancy L Bartlett, Paul M Barr, Haematologica
• Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath stromal cells in culture.  
  18. Burger JA, M Burger, and TJ Kipps, Blood 94: 3658-3667
• Blood-derived”nurse-like” cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis via stromal cell-derived factor-1.  
  Burger JA, N Tsukada, M Burger, NJ Zvaifler, M Dell’Aquila, and TJ Kipps, Plenary Paper, Blood 96 (8) : 2655-63
• The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.  
  Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA, Blood. 2;119(5):1182-9
• The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.  
  Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA, Blood. 118(13):3603-12
• CCL3 (MIP-1?) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.  
  Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rose..., Blood.;117(5):1662-9
• B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel Syk inhibitor, R406.  
  Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda, WG, Gandhi V, Burger JA, Blood 114:1029-37
• Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in CLL: a novel therapeutic approach.  
  10. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda, WG, Keating MJ, Shokat KM, Burger JA, Blood 113:5549-57
• High-Level Expression of the T Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B cells in nurselike cell co-cultures and after BCR stimulation.  
  Burger JA, Quiroga M, Hartmann E, Bürkle A, Wierda WG, Keating MJ, and Rosenwald A, Blood 113:3050-8
• Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B cell chronic lymphocytic leukemia.  
  Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA, Blood. 110:3316-25
• CXCR4 is a prognostic marker in Acute Myelogenous Leukemia.  
  Spoo AC, Lubbert M, Wierda WG, Burger JA, Blood 109:786-791
• A Key Receptor In The Cross Talk Between Tumor Cells And Their Microenvironment.  
  Burger JA, and Kipps TJ: CXCR4, Blood 107(5): 1761-7
• Small Peptide Inhibitors of the CXCR4 Chemokine Receptor (CD184) Antagonize the Activation, Migration and Antiapoptotic Responses of CXCL12 in Chronic Lymphocytic Leuk...  
  Burger M, Hartmann T, Rawluk J, Tamamura H, Fujii N, Kipps TJ, and Burger JA, Blood 106(5):1824-30
• Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism.  
  Burger JA, NJ Zvaifler, N Tsukada, GS Firestein, and TJ Kipps, Journal of Clinical Investigation 107 (3): 305-15
• Join now to see all

Abstracts/Posters

• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
  Jan A. Burger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Importance of B Cell Receptor Isotypes and Stereotypes in Chronic Lymphocytic Leukemia
  Jan Burger, MD, Nature, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all